Propafenone is an antiarrhythmic drug that produces a variable degree of P3-blockade in humans and is administered as a racemate. To examine the relative contribution of the individual enantiomers to pharmacologic effects seen during treatment with propafenone, we assessed the steady-state plasma concentrations of (+)-S-propafenone and (-)-R-propafenone in seven patients who were on long-term oral therapy, and we evaluated the electrophysiologic and p3-blocking properties of both enantiomers in vitro. The metabolism of propafenone is known to be polymorphic and to cosegregate with that of debrisoquine-4-hydroxylation. Among five patients with the extensive metabolizer phenotype (EM), the ratio of the area under the plasma concentration-time curve of (+)-S-propafenone to (-)-R-propafenone was 1.73+±0.15 (mean+SD). In the other two patients, who had the poor metabolizer phenotype (PM), the concentrations of both enantiomers were elevated but the SIR ratios were similar to those seen in patients with EM. In canine cardiac Purkinje fibers, both enantiomers produced similar frequency-dependent depression of maximum upstroke of phase 0. In contrast, the affinity of the human lymphocyte 1-adrenoceptor was approximately 100-fold greater for (+)-S-propafenone (K, 7.2±2.9 nM) than for the (-)-R-enantiomer (K;, 571±141 nM). We conclude that during Propafenone is administered as a racemic mixture of (+)-S-and (-)-R-enantiomers. Pharmacokinetic differences between the enantiomers of other racemic drugs, such as metoprolol and N-propylajmaline, which are substrates for P-450db1, have been found in EM but not in PM subjects, indicating the potential for stereoselective metabolism of substrates for this cytochrome P 450.9, 1 The in vitro electrophys-
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Similarly 
High-Performance Liquid Chromatography Deternination of Propafenone Enantiomers
The concentrations of (+)-S-propafenone and (-)-R-propafenone were determined by a highperformance liquid chromatography assay. One milliliter of plasma was spiked with 500 ng internal standard (2'-(2-hydroxy-3-ethylamino-propoxy)-3-phenyl-propiophenone hydrochloride, Knoll Pharmaceuticals, Whippany, New Jersey), alkalinized with 0.1 M Tris buffer (pH 12.0), and shaken with 6 ml diethylether for 10 minutes. After centrifugation, the organic layer was transferred to a conical tube, and 200 gl 0.5N phosphoric acid was added. The tube was shaken for 10 minutes and centrifuged, and the organic layer was removed. The acid phase was alkalinized again with 2N NaOH, and 5 ml dichloromethane was added. The mixture was shaken for 10 minutes and centrifuged. The 10 .0 minutes for the GITC derivative of (+)-S-propafenone, and 11.5 minutes for derivatized (-)-R-propafenone. Calibration curves were established in plasma for each individual enantiomer and were linear in a range of 0 to 1,000 ng/ml (r=0.99) for the (+)-S-propafenone and the (-)-R-enantiomer (r=0.99). The purity of the enantiomers exceeded 98%. Recovery averaged 40%, presumably reflecting the multistep extraction. The detection limit was 100 ng/ml.
The Before each study, the preparation was stimulated at a basic cycle length of 1,000 msec for 30 minutes to ensure stability of the impalement. The preparation was then stimulated over a wide range of frequencies (300-8,000 msec), and a Polaroid photograph was taken of the oscilloscope screen once action potentials had stabilized at each frequency. After baseline data were obtained, the preparation was superfused for 30 minutes with Tyrode's solution containing 1 ,uM of either (+)-S-propafenone or (-)-R-propafenone and the entire baseline protocol was repeated. Action potential characteristics, including action potential amplitude, takeoff potential, overshoot, and action potential duration at 50% and 90% repolarization (APD50 and APD90, respectively), were measured from each photograph with a digitizing board (Bit Pad One, Summagraphic Corp, Fairfield, Connecticut) connected to a microcomputer. Vmax was measured directly with the differentiated 200 V/sec signal and a permanent measurement scale on the oscilloscope, both of which were present on each photograph.
Affinity of (32-Adrenoceptors for
Propafenone Enantiomers
Blood was drawn from five healthy, drug-free, nonsmoking male volunteers (age, 22-29 years) using ethylenediamine tetraacetic acid (EDTA) as the anticoagulant. Mononuclear leukocyte (MNL) membranes were prepared according to a modification of a previously described method. Tris-HCl (pH 7.6 at 370 C), 60 mM NaCl, 9 mM MgCl2, 1.8 mM EDTA, 3.6 mM sucrose, 4 ng/ml BSA, and 0.5 mM ascorbic acid. The binding reaction was stopped by the addition of 10 ml wash buffer containing 10 mM Tris-HCl (pH 7.6 at 370 C), 90 mM NaCl, 15 mM MgCl2, and 3 mM EDTA. Samples were filtered through Whatman GF/C filters, and filters were then washed with an additional 10 ml wash buffer and dried by vaccum filtration at a pressure of 15-20 psi. Radioactivity retained on the filters was determined in a gamma counter (Beckmann Gamma 5500 normal distribution of the data. Correlation between metabolic ratio and clearance was evaluated by Spearman's rank correlation test.
Results

Stereoselective Disposition of Propafenone Enantiomers
Typical chromatograms using the HPLC system described above are shown in Figure 2 . A baseline separation between the enantiomers was achieved. Figure 3 shows the time versus plasma concentration profile for one patient with EM. During the 8 hours of interdose sampling, plasma concentrations of (+)-S-propafenone were greater than those of (-)-R-propafenone. The results of the pharmacokinetec calculations are summarized in Table 1 . The AUCT for (+)-S-propafenone was 1.73±+0.15 (range, 1.56-1.92) times greater than that of the (-)-R-propafenone (p<0.002) in the EM group, indicating that the latter compound is cleared 1.7 times faster than (+)-S-propafenone. Clearance of both enantiomers was reduced in the two patients with PM (Table 1 ) but remained stereoselective. The clearance of both enantiomers correlated well with the metabolic ratio of debrisoquine/4-hydroxy debrisoquine in the five patients in whom an accurate metabolic ratio was obtained (Figure 4 ).
Electrophysiologic Studies
(+)-S-Propafenone and (-)-R-propafenone (n =6 each) both depressed Vm in a frequency-dependent manner ( Figure 5 ). The effect was significantly different from baseline at the shorter basic cycle lengths-300, 500, and 1,000 msec. A comparison between the enantiomers showed a trend toward a greater effect of (+)-S-propafenone (Vmax, 80.2+8.8% of baseline) compared with (-)-R-propafenone (88.4±4.5% of baseline) at fast rates (basic cycle length, 300 msec), but the difference was not statistically significant (p <0.069). shown in Figure 7 . Propafenone enantiomers did not alter action potential duration at 90% repolarization, action potential amplitude, overshoot, and the takeoff potential. Affinity of f32-Adrenoceptors for Propafenone Enantiomers Each compound displaced`251-iodopindolol from /32-adrenoceptors on MNL membranes. The displacement curve of (+)-S-propafenone was shifted to the left compared with the (-)-R-enantiomer (Figure 8) . The values of Ki and IC50 indicated that the affinity of (+)-S-propafenone for the /82-adrenoceptor was about 100 times greater than that for (-)-R-propafenone (Table 2) . Differences between the enantiomers for both IC50 and Ki were highly significant (p<0.005).
Discussion
Pharmacokinetic and pharmacodynamic profiles of drug enantiomers have gained increasing attention in the clinical evaluation of new compounds.27 Several consequences of stereoselective drug metabolism that might have important implications for the therapeutic effect of a drug have been described by Eichelbaum.28 First, stereoselective first-pass metabolism can cause different concentration-response relations depending on the route of administration (e.g., verapamil29). Second, stereoselective drug interactions may have important therapeutic implications if the enantiomers have substantially differing potencies (e.g., warfarin30). Third, stereoselective drug oxidation may be phenotype dependent. This has been investigated in detail for metoprolol9 and N-propylajmaline.10 Both drugs undergo polymorphic oxidation of the debrisoquine type. Differences in the pharmacokinetics of the enantiomers were shown in patients with EM, while patients with PM were characterized by a loss of stereoselectivity. In the present study, we have shown that (-)-R-propafenone is cleared faster than (+)-S-propafenone in patients with EM, leading to a higher concentration of the (+)-S-enantiomer in plasma. In contrast to metoprolol and Npropylajmaline, the two patients with PM included in our study exhibited a similar degree of enantioselective disposition as those with EM. The major oxidative metabolic pathways of propafenone during long-term oral therapy in humans are 5-hydroxylation and N-dealkylation. 31 In PMs of propafenone, 5-hydroxylation is impaired and the apparent oral clearance of propafenone is dramatically reduced.2132 Thus, routes of metabolism other than 5-hydroxylation contribute to the stereoselective disposition of propafenone during longterm oral therapy. This conclusion is further supported by the fact that we did not observe significant changes in stereoselective steady-state disposition of propafenone after coadministration of quinidine (H. Kroemer, unpublished results) , an inhibitor of propafenone 5-hydroxylation. 32 However, stereoselective drug disposition is of little consequence if the enantiomers produce similar pharmacologic actions. Consequently, the other Figure  5 ). Thus, the depression of the fast inward sodium channel is not sensitive for steric differences of propafenone enantiomers, suggesting that the puta- Because (+)-S-propafenone was found to be about 100 times more potent than (-)-R-propafenone, we conclude that (+)-S-propafenone is responsible for the ,B-blocking properties of propafenone. This is in contrast to propranolol where the (-)-enantiomer is the more potent 8-blocker. 15 However, determination of the configuration has shown that the (+)-enantiomer of propafenone has the S-configuration,39 whereas the (+)-enantiomer of propranolol has the R-configuration. Therefore, for both agents, the Sconfigured enantiomer appears responsible for 1- blockade.
Integration of the three parts of our study allows us to make some inferences on the role of propafenone enantiomers in man. Regardless of phenotype, (+)-S-propafenone is predominant in plasma. As a consequence of their impaired metabolism, subjects with PM have a decreased clearance and substantially higher plasma levels than those with EM for (-)-R-propafenone and (+)-S-propafenone. Thus, the PM subset is more likely to develop p-blocking effects because the latter compound is responsible for 8-blocking effects of propafenone. In agreement are recent findings of Lee et al,20 who described a greater degree of p-blockade in those with PM. A simple reduction of the propafenone dose in those with PM may lead to reduced therapeutic effect because those with PM lack the ability to form 5-hydroxy propafenone, which contributes to the sodium channel-blocking effect.7,32 Therefore, higher plasma levels of the parent compound are required in those with PM than in those with EM to achieve similar suppression of arrhythmias. Because (+)-S-propafenone and (-)-R-propafenone have comparable sodium channel-blocking activities, the (-)-R-propafenone may suppress arrhythmias without blocking p-adrenoceptors and may be of advantage for therapy in those at risk for 3-mediated side effects. Conversely, therapy with the (+)-S-enantiomer may produce greater arrhythmia suppression in those patients in whom a combined sodium channel and ,8-blocking effect is desirable.
